HIV Clinical Trial
Official title:
Investigation of Incentives to Promote Medication Adherence Among HIV-Infected Youth on Antiretroviral Therapy
Medication adherence is one of the most salient predictors of patient outcomes in the era following development of effective treatment for HIV infection. Evolving strategies to improve adherence, specifically incentive interventions and real-time medication monitoring, have shown some success in limited studies. Further investigation into incentive interventions for HIV-infected adolescents with poor medication adherence is necessary.
| Status | Completed |
| Enrollment | 25 |
| Est. completion date | June 2016 |
| Est. primary completion date | June 2016 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 16 Years to 24 Years |
| Eligibility |
Inclusion Criteria: - =16 and = 24 years old - Documented diagnosis of HIV - Adolescent is aware of his/her HIV diagnosis - Adolescent understands either written or spoken English. - Adolescent is willing and able to provide informed consent or assent. - Adolescent has access to a phone and the internet at the time of enrollment. - Adolescent meets the definition of inadequate ARV adherence, which is any of the following in the previous 12 months: - < 80% adherent to any ARV by pharmacy pill count - = 7 days delay in scheduled ARV prescription pick-up - Detectable viral load after being on ARVs for at least 12 weeks Exclusion Criteria: - Adolescent has a documented diagnosis of mental retardation or a significant motor or sensory impairment that would preclude participation. - Adolescent has a documented acute psychiatric illness, including suicidal ideation, homicidal ideation or active psychosis. - Adolescent was diagnosed with HIV in the previous 6 months. - Adolescent has a planned transition to alternative care setting prior to study completion (e.g. relocation, pregnancy or planned pregnancy, transition to adult care). - Concurrent enrollment on a research study with an intervention targeted at increasing adherence to antiretroviral regimens. |
Observational Model: Cohort, Time Perspective: Prospective
| Country | Name | City | State |
|---|---|---|---|
| United States | St. Jude Children's Research Hospital | Memphis | Tennessee |
| Lead Sponsor | Collaborator |
|---|---|
| St. Jude Children's Research Hospital |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Percentage of dosages taken within 2 hours of prescribed time per month | Data collected by a real-time medication monitor that records pillbox opening times. | Monthly through week 48 | No |
| Primary | Pharmacy pill count | Pharmacy pill count data is collected at each participant encounter, approximately once per month. | Monthly from 6 months prior to study start through week 48 | No |
| Secondary | Feasibility - Accrual percentage | Number of people enrolled in study/number approached for enrollment. | End of study (week 48) | No |
| Secondary | Feasibility - Drop out rate | Number of people ending protocol early/ total enrollment | End of study (week 48) | No |
| Secondary | Feasibility - Participant reported device concerns | Problems with the Wisepill devices as spontaneously reported by participants or as assessed at routine follow-up. | End of study (week 48) | No |
| Secondary | Feasibility - Device replacement rate | Number of devices requiring replacement due to loss/theft/breakage | End of study (week 48) | No |
| Secondary | Feasibility - Contact failure rate | Number of failed attempts to contact participants/total number of contact attempts made | End of study (week 48) | No |
| Secondary | Feasibility - Staff hours per week | Hours spent providing remote incentives | End of study (week 48) | No |
| Secondary | Feasibility - Adverse effects of incentives | Unexpected risks/harms of providing incentives as self-reported by participants. | End of study (week 48) | No |
| Secondary | Percentage of participants who are satisfied with the incentive intervention | To assess participant satisfaction with the incentive intervention model. Patient satisfaction, assessed by ACASI survey, will be summarized and tabulated for baseline (week 0) and follow-up (week 48) measurements. | Enrollment (week 0) and end of study (week 48) | No |
| Secondary | Effect of incentives on missed appointment rate | Descriptive statistics of numbers of missed appointments such as mean, interquartile range and median, during each study phase will be computed and compared | Enrollment (week 0) and end of study (week 48) | No |
| Secondary | Effect of incentives on STI rates | Descriptive statistics of numbers of STI rates such as mean, interquartile range and median, during each study phase will be computed and compared | Enrollment (week 0) and end of study (week 48) | No |
| Secondary | Change in biological parameters | To measure the effect of the incentive intervention on HIV viral load and CD4+ count. HIV viral load and CD4+ count measured at week 0, 12, 24, 36 and 48 will be summarized and plotted by descriptive statistics, such as mean and standard deviation. Mixed effects models will be applied to explore the effect of the intervention on HIV viral load and CD4+ count. | At weeks 0, 12, 24, 36 and 48 | No |
| Secondary | Overall cost of incentive intervention | To determine the overall and per patient cost of the incentive intervention model the accumulated overall and per patient cost till week 48 will be summarized and tabulated. | End of study (week 48) | No |
| Secondary | Association between adherence measures | To describe associations between adherence measures: Wisepill data, pharmacy pill count, pharmacy prescription pick-up data, medication possession ratio, and self-report. Associations of Wisepill adherence rates with pill count and pick up rates will be described by Pearson or Spearman's correlation coefficients and intraclass correlation coefficients as appropriate. | End of study (week 48) | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
| Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
| Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
| Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
| Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
| Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
| Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
| Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
| Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
| Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
| Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
| Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
| Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
| Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
| Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
| Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
| Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
| Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
| Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |